ALK and non-small cell lung carcinoma: As a result of advances in targeted therapies for various biomarkers, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and immunotherapies targeting programmed death-ligand 1 (PD-L1), the landscape of advanced NSCLC treatment is changing [5].